Clinical utility of HIV-IgA immunoblot assay in the early diagnosis of perinatal HIV infection

Sheldon Landesman, Barbara Weiblen, Herman Mendez, Anne Willoughby, James J. Goedert, Arye Rubinstein, Howard Minkoff, Gail Moroso, Rod Hoff

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Objective.-To ascertain the sensitivity, specificity, predictive value, and clinical use of a human immunodeficiency virus (HIV)-IgA immunoblot assay for diagnosing perinatal HIV infection in infants tested at birth to 1 month, 3 months, and 6 months of age. Design.-Prospective, longitudinal cohort study of children born to HIV-infected and noninfected women. The HIV-IgA immunoblot assays were performed at birth to 1 month, 3 months, and 6 months of age and compared with the Centers for Disease Control's classification system of HIV infection in the children. Children were followed up for at least 15 months to ensure accuracy of infection status. Setting.-Municipal hospital in central Brooklyn, NY, where the prevalence of HIV infection is high. Patients.-Serum samples from 58 children, 22 with documented HIV infection, 18 noninfected children born to seropositive women, and 18 children born to noninfected women, were studied. Main Outcome Measure.-Diagnosis of HIV infection using the Centers for Disease Control's classification scheme was compared with diagnosis using the HIV-IgA immunoblot assay for children 6 months of age or younger. Results.-The HIV-IgA immunoblot assay yielded negative results at 3 and 6 months of age for all 18 infants born to seronegative women; for the 18 seroreverting, noninfected children born to infected women, the assay yielded negative results at 1 month, 3 months, and 6 months of age. The positive predictive value of the assay was 100%-no false-positive results were identified in the 88 serum samples obtained from noninfected infants. For the HIV-infected children, sensitivity was a function of age: one (5.9%) of 17 infants had an assay that yielded positive results at birth to 1 month of age, 13 (62%) of 21 infants had assays that yielded positive results at 3 months of age, and 17 (77%) of 22 infants had assays that yielded positive results at 6 months of age. The presence or absence of symptoms did not affect the sensitivity. Conclusion.-The HIV-IgA immunoblot assay can detect a significant proportion of infected children during an early asymptomatic period of their life. This relatively inexpensive, easily standardized assay may allow for institution of therapy before the onset of clinical symptoms.

Original languageEnglish (US)
Pages (from-to)3443-3446
Number of pages4
JournalJournal of the American Medical Association
Volume266
Issue number24
StatePublished - 1991

Fingerprint

Virus Diseases
Immunoglobulin A
Early Diagnosis
HIV
Parturition
Centers for Disease Control and Prevention (U.S.)
Municipal Hospitals
Serum
Longitudinal Studies
Cohort Studies
Outcome Assessment (Health Care)
Sensitivity and Specificity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Landesman, S., Weiblen, B., Mendez, H., Willoughby, A., Goedert, J. J., Rubinstein, A., ... Hoff, R. (1991). Clinical utility of HIV-IgA immunoblot assay in the early diagnosis of perinatal HIV infection. Journal of the American Medical Association, 266(24), 3443-3446.

Clinical utility of HIV-IgA immunoblot assay in the early diagnosis of perinatal HIV infection. / Landesman, Sheldon; Weiblen, Barbara; Mendez, Herman; Willoughby, Anne; Goedert, James J.; Rubinstein, Arye; Minkoff, Howard; Moroso, Gail; Hoff, Rod.

In: Journal of the American Medical Association, Vol. 266, No. 24, 1991, p. 3443-3446.

Research output: Contribution to journalArticle

Landesman, S, Weiblen, B, Mendez, H, Willoughby, A, Goedert, JJ, Rubinstein, A, Minkoff, H, Moroso, G & Hoff, R 1991, 'Clinical utility of HIV-IgA immunoblot assay in the early diagnosis of perinatal HIV infection', Journal of the American Medical Association, vol. 266, no. 24, pp. 3443-3446.
Landesman, Sheldon ; Weiblen, Barbara ; Mendez, Herman ; Willoughby, Anne ; Goedert, James J. ; Rubinstein, Arye ; Minkoff, Howard ; Moroso, Gail ; Hoff, Rod. / Clinical utility of HIV-IgA immunoblot assay in the early diagnosis of perinatal HIV infection. In: Journal of the American Medical Association. 1991 ; Vol. 266, No. 24. pp. 3443-3446.
@article{cface8350ce74e7e8c1100a9a5ff842d,
title = "Clinical utility of HIV-IgA immunoblot assay in the early diagnosis of perinatal HIV infection",
abstract = "Objective.-To ascertain the sensitivity, specificity, predictive value, and clinical use of a human immunodeficiency virus (HIV)-IgA immunoblot assay for diagnosing perinatal HIV infection in infants tested at birth to 1 month, 3 months, and 6 months of age. Design.-Prospective, longitudinal cohort study of children born to HIV-infected and noninfected women. The HIV-IgA immunoblot assays were performed at birth to 1 month, 3 months, and 6 months of age and compared with the Centers for Disease Control's classification system of HIV infection in the children. Children were followed up for at least 15 months to ensure accuracy of infection status. Setting.-Municipal hospital in central Brooklyn, NY, where the prevalence of HIV infection is high. Patients.-Serum samples from 58 children, 22 with documented HIV infection, 18 noninfected children born to seropositive women, and 18 children born to noninfected women, were studied. Main Outcome Measure.-Diagnosis of HIV infection using the Centers for Disease Control's classification scheme was compared with diagnosis using the HIV-IgA immunoblot assay for children 6 months of age or younger. Results.-The HIV-IgA immunoblot assay yielded negative results at 3 and 6 months of age for all 18 infants born to seronegative women; for the 18 seroreverting, noninfected children born to infected women, the assay yielded negative results at 1 month, 3 months, and 6 months of age. The positive predictive value of the assay was 100{\%}-no false-positive results were identified in the 88 serum samples obtained from noninfected infants. For the HIV-infected children, sensitivity was a function of age: one (5.9{\%}) of 17 infants had an assay that yielded positive results at birth to 1 month of age, 13 (62{\%}) of 21 infants had assays that yielded positive results at 3 months of age, and 17 (77{\%}) of 22 infants had assays that yielded positive results at 6 months of age. The presence or absence of symptoms did not affect the sensitivity. Conclusion.-The HIV-IgA immunoblot assay can detect a significant proportion of infected children during an early asymptomatic period of their life. This relatively inexpensive, easily standardized assay may allow for institution of therapy before the onset of clinical symptoms.",
author = "Sheldon Landesman and Barbara Weiblen and Herman Mendez and Anne Willoughby and Goedert, {James J.} and Arye Rubinstein and Howard Minkoff and Gail Moroso and Rod Hoff",
year = "1991",
language = "English (US)",
volume = "266",
pages = "3443--3446",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "24",

}

TY - JOUR

T1 - Clinical utility of HIV-IgA immunoblot assay in the early diagnosis of perinatal HIV infection

AU - Landesman, Sheldon

AU - Weiblen, Barbara

AU - Mendez, Herman

AU - Willoughby, Anne

AU - Goedert, James J.

AU - Rubinstein, Arye

AU - Minkoff, Howard

AU - Moroso, Gail

AU - Hoff, Rod

PY - 1991

Y1 - 1991

N2 - Objective.-To ascertain the sensitivity, specificity, predictive value, and clinical use of a human immunodeficiency virus (HIV)-IgA immunoblot assay for diagnosing perinatal HIV infection in infants tested at birth to 1 month, 3 months, and 6 months of age. Design.-Prospective, longitudinal cohort study of children born to HIV-infected and noninfected women. The HIV-IgA immunoblot assays were performed at birth to 1 month, 3 months, and 6 months of age and compared with the Centers for Disease Control's classification system of HIV infection in the children. Children were followed up for at least 15 months to ensure accuracy of infection status. Setting.-Municipal hospital in central Brooklyn, NY, where the prevalence of HIV infection is high. Patients.-Serum samples from 58 children, 22 with documented HIV infection, 18 noninfected children born to seropositive women, and 18 children born to noninfected women, were studied. Main Outcome Measure.-Diagnosis of HIV infection using the Centers for Disease Control's classification scheme was compared with diagnosis using the HIV-IgA immunoblot assay for children 6 months of age or younger. Results.-The HIV-IgA immunoblot assay yielded negative results at 3 and 6 months of age for all 18 infants born to seronegative women; for the 18 seroreverting, noninfected children born to infected women, the assay yielded negative results at 1 month, 3 months, and 6 months of age. The positive predictive value of the assay was 100%-no false-positive results were identified in the 88 serum samples obtained from noninfected infants. For the HIV-infected children, sensitivity was a function of age: one (5.9%) of 17 infants had an assay that yielded positive results at birth to 1 month of age, 13 (62%) of 21 infants had assays that yielded positive results at 3 months of age, and 17 (77%) of 22 infants had assays that yielded positive results at 6 months of age. The presence or absence of symptoms did not affect the sensitivity. Conclusion.-The HIV-IgA immunoblot assay can detect a significant proportion of infected children during an early asymptomatic period of their life. This relatively inexpensive, easily standardized assay may allow for institution of therapy before the onset of clinical symptoms.

AB - Objective.-To ascertain the sensitivity, specificity, predictive value, and clinical use of a human immunodeficiency virus (HIV)-IgA immunoblot assay for diagnosing perinatal HIV infection in infants tested at birth to 1 month, 3 months, and 6 months of age. Design.-Prospective, longitudinal cohort study of children born to HIV-infected and noninfected women. The HIV-IgA immunoblot assays were performed at birth to 1 month, 3 months, and 6 months of age and compared with the Centers for Disease Control's classification system of HIV infection in the children. Children were followed up for at least 15 months to ensure accuracy of infection status. Setting.-Municipal hospital in central Brooklyn, NY, where the prevalence of HIV infection is high. Patients.-Serum samples from 58 children, 22 with documented HIV infection, 18 noninfected children born to seropositive women, and 18 children born to noninfected women, were studied. Main Outcome Measure.-Diagnosis of HIV infection using the Centers for Disease Control's classification scheme was compared with diagnosis using the HIV-IgA immunoblot assay for children 6 months of age or younger. Results.-The HIV-IgA immunoblot assay yielded negative results at 3 and 6 months of age for all 18 infants born to seronegative women; for the 18 seroreverting, noninfected children born to infected women, the assay yielded negative results at 1 month, 3 months, and 6 months of age. The positive predictive value of the assay was 100%-no false-positive results were identified in the 88 serum samples obtained from noninfected infants. For the HIV-infected children, sensitivity was a function of age: one (5.9%) of 17 infants had an assay that yielded positive results at birth to 1 month of age, 13 (62%) of 21 infants had assays that yielded positive results at 3 months of age, and 17 (77%) of 22 infants had assays that yielded positive results at 6 months of age. The presence or absence of symptoms did not affect the sensitivity. Conclusion.-The HIV-IgA immunoblot assay can detect a significant proportion of infected children during an early asymptomatic period of their life. This relatively inexpensive, easily standardized assay may allow for institution of therapy before the onset of clinical symptoms.

UR - http://www.scopus.com/inward/record.url?scp=0026431851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026431851&partnerID=8YFLogxK

M3 - Article

VL - 266

SP - 3443

EP - 3446

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 24

ER -